SCHEMBL3270441

SCHEMBL3270441

COc1ccc(C2(C(=O)N3CCOCC3)CCOCC2)cc1

nearest known ligand 0.87

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.87
CYP2C19 P33261 1/20 0.87
HPGD P15428 1/20 0.66
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
ALDH1A1 P00352 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.57
LMNA P02545 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
POLB P06746 3/20 0.56
EP300 Q09472 1/20 0.54
FKBP1A P62942 2/20 0.53
AKR1C3 P42330 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21965004 0.93 CYP3A4 (0.81) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL3272757 0.91 CYP2C19 (0.73) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL21961586 0.81 CYP3A4 (0.80) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL21965003 0.81 CYP3A4 (0.75) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL31525688 0.81 ALDH1A1 (0.60) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL1466916 0.81 POLB (0.62) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL15075120 0.80 HPGD (1.00) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL21961616 0.80 CYP3A4 (0.78) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL21964271 0.80 CYP3A4 (0.78) CYP3A4CYP2C19HPGDMEN1KMT2A
SCHEMBL18390063 0.80 CYP3A4 (0.65) CYP3A4CYP2C19MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747210-B1 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS WARNER LAMBERT CO (US) 2010-06-30 EP disclosed
US-7456164-B2 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable PFIZER, INC (US) 2008-11-25 US disclosed
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands ZIARCO INC. 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands HRH4, HRH3, TLR4 CYP3A4 104/4885CYP2C19 854/4885HPGD 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.